⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163442 | 0.69 | — | — | |
| SCHEMBL1035336 | 0.67 | — | — | |
| SCHEMBL5160944 | 0.61 | — | — | |
| SCHEMBL5163624 | 0.59 | — | — | |
| SCHEMBL11223089 | 0.55 | — | — | |
| SCHEMBL11457264 | 0.55 | — | — | |
| SCHEMBL1343779 | 0.55 | — | — | |
| SCHEMBL586833 | 0.50 | — | — | |
| SCHEMBL11816980 | 0.50 | GSK3A (0.41) | — | |
| SCHEMBL5597052 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678442-A | Novel aniline compound | PI工业有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20160318897-A1 | AZOLE COMPOUNDS CARRYING AN IMINE-DERIVED SUBSTITUENT | BASF SE (DE) | 2016-11-03 | — | — | US | disclosed |
| CN-103819416-A | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | EXELIXIS INC | 2014-05-28 | — | — | CN | disclosed |
| CN-103202842-A | Methods Of Treating By Inhibiting With Quinaxoline Inhibitors Of P13k-alpha | EXELIXIS INC | 2013-07-17 | — | — | CN | disclosed |
| CN-101959516-B | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2013-05-08 | — | — | CN | disclosed |
| WO-2009115267-A2 | DIAMINOPYRIMIDINES AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AG (DE) | 2009-09-24 | — | — | WO | disclosed |